FZ 003
Alternative Names: FZ-003Latest Information Update: 30 Jun 2023
At a glance
- Originator Guangzhou Fermion Technology
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Breast cancer; Glioma
Most Recent Events
- 23 Jun 2023 FZ 003 is available for licensing as of 23 Jun 2023. https://www.fulmz.com/pipeline
- 23 Jun 2023 Preclinical trials in Breast cancer in China (unspecified route) prior to June 2023 (Guangzhou Fermion Technology, June 2023)
- 23 Jun 2023 Preclinical trials in Glioma in China (unspecified route) prior to June 2023 (Guangzhou Fermion Technology, June 2023)